☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
gsk
GSK Highlights Full Results from the P-III (SWIFT-1 and SWIFT-2) Trials of Depemokimab for Treating Severe Asthma at ERS 2024
September 10, 2024
GSK Reports the P-III Study Results of Nucala (Mepolizumab) for Treating Chronic Obstructive Pulmonary Disease (COPD)
September 6, 2024
GSK’s Arexvy Vaccine Receives the EC’s Approval for its Expanded Age Indication to Prevent Lower Respiratory Tract Disease (LRTD)
August 29, 2024
GSK’s Nucala (Mepolizumab) Receives Japanese Approval for Treating Chronic Rhinosinusitis with Nasal Polyps
August 28, 2024
GSK’s GSK5764227 (GSK’227) Gets the US FDA’s Breakthrough Therapy Designation for r/r Extensive-Stage Small-Cell Lung Cancer (ES-S...
August 20, 2024
GSK Reports the US FDA’s Expanded Approval of Jemperli Plus Chemotherapy for Treating Endometrial Cancer
August 2, 2024
Load more...
Back to Home